A new meta-analysis of more than 6000 studies shows that oral contraceptives significantly reduce the risk of ovarian cancer. The risk reduction increases proportionally with duration of use.
See the abstract here
Related Topics
OCRA’s Advocate’s Corner: July 2025
Written by Chad Ramsey, Vice President, Policy, Ovarian Cancer Research Alliance FY26 Budget & Appropriations Update: Approaching August with Focused Advocacy As Congress advances the FY 2026 appropriations process, gynecologic cancer advocates … Continued
Action Alert: Urge Congress to Reject Cuts to Vital Cancer Programs
Stop Cuts to Education, Screening & Surveillance Programs The President’s proposed budget for Fiscal Year 2026 would eliminate the CDC’s Division of Cancer Prevention and Control (DCPC). This division supports … Continued
OCRA’s Advocate’s Corner: June 2025
Written by Chad Ramsey, Vice President, Policy, Ovarian Cancer Research Alliance FY26 Budget Update: Critical Cancer Programs at Risk Congress is deep into its work on the fiscal year 2026 … Continued